AADvac1, an active immunotherapy against pathological tau protein demonstrates disease-modifying effects in Alzheimer's disease: a placebo-controlled randomised phase 2 study.

John Harrison

AADvac1, an active immunotherapy against pathological tau protein demonstrates disease-modifying effects in Alzheimer's disease: a placebo-controlled randomised phase 2 study.

Centre for Affective Disorders

Research output: Contribution to journal › Article › peer-review

Original language	English
Journal	Nature Medicine
Publication status	Accepted/In press - 1 Mar 2021

Cite this

@article{0ce33ed8e2d348cd8e16c955de89557c,

title = "AADvac1, an active immunotherapy against pathological tau protein demonstrates disease-modifying effects in Alzheimer's disease: a placebo-controlled randomised phase 2 study.",

author = "John Harrison",

year = "2021",

month = mar,

day = "1",

language = "English",

journal = "Nature Medicine",

issn = "1078-8956",

publisher = "Nature Publishing Group",

}